Skip to main content
HR 1834 115th Congress House Health Cancer Cardiovascular and respiratory health Digestive and metabolic diseases Drug therapy Emergency medical services and trauma care Health care quality Health information and medical records Home and outpatient care Long-term, rehabilitative, and terminal care Medicare Performance measurement Women's health

Cancer Care Payment Reform Act of 2017

Introduced: March 30, 2017 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 12, 2017
Referred to the Subcommittee on Health.
Mar 31, 2017
Referred to the Subcommittee on Health.
Mar 30, 2017
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 30, 2017
Introduced in House
 Plain-English summary Congressional Research Service

Cancer Care Payment Reform Act of 2017

This bill amends title XVIII (Medicare) of the Social Security Act to establish the Oncology Medical Home Demonstration Project, through which the Centers for Medicare & Medicaid Services (CMS) shall make special payments to participating oncology practices that coordinate patient care and meet other specified requirements.

During the first two years of the project, CMS shall pay a care coordination management fee to each such practice. After the third, fourth, and fifth years of the project, CMS shall pay a performance incentive payment to each participating practice that meets or exceeds performance standards developed by CMS.

CMS shall assess the performance of each participating oncology practice annually. Performance standards shall address: (1) specified measures related to patient care, resource utilization, survivorship, and end-of-life care; and (2) the patient experience of care, as reflected in surveys submitted by each practice. CMS shall also assess the extent to which a practice has used breakthrough or other best-in-class therapies.

To the extent practicable, CMS shall select practices of varying sizes and geographic areas for participation.

What's happening now April 12, 2017

Referred to the Subcommittee on Health.

 Committees of jurisdiction 4
 Cosponsors 1
All 1 Democratic 1